| Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology RJ Motzer, E Jonasch, N Agarwal, S Bhayani, WP Bro, SS Chang, ... Journal of the National Comprehensive Cancer Network 15 (6), 804-834, 2017 | 564 | 2017 |
| Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer ET Lam, MD Ringel, RT Kloos, TW Prior, MV Knopp, J Liang, S Sammet, ... Journal of Clinical Oncology 28 (14), 2323, 2010 | 427 | 2010 |
| Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology RJ Motzer, E Jonasch, N Agarwal, A Alva, M Baine, K Beckermann, ... Journal of the National Comprehensive Cancer Network 20 (1), 71-90, 2022 | 372 | 2022 |
| Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2α antagonist in patients with previously treated advanced clear cell renal cell carcinoma KD Courtney, JR Infante, ET Lam, RA Figlin, BI Rini, J Brugarolas, ... Journal of Clinical Oncology 36 (9), 867, 2018 | 356 | 2018 |
| Kidney cancer, version 3.2015 RJ Motzer, E Jonasch, N Agarwal, C Beard, S Bhayani, GB Bolger, ... Journal of the National Comprehensive Cancer Network 13 (2), 151-159, 2015 | 259 | 2015 |
| Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1. M Smith, J De Bono, C Sternberg, S Le Moulec, S Oudard, U De Giorgi, ... LIPPINCOTT WILLIAMS & WILKINS, 2016 | 241 | 2016 |
| NCCN guidelines insights: kidney cancer, version 2.2020: featured updates to the NCCN guidelines RJ Motzer, E Jonasch, MD Michaelson, L Nandagopal, JL Gore, S George, ... Journal of the National Comprehensive Cancer Network 17 (11), 1278-1285, 2019 | 211 | 2019 |
| NCCN guidelines insights: kidney cancer, version 1.2021: featured updates to the NCCN guidelines RJ Motzer, E Jonasch, S Boyle, MI Carlo, B Manley, N Agarwal, A Alva, ... Journal of the National Comprehensive Cancer Network 18 (9), 1160-1170, 2020 | 203 | 2020 |
| Renal cell carcinoma: a review of biology and pathophysiology S Nabi, ER Kessler, B Bernard, TW Flaig, ET Lam F1000Research 7, 2018 | 166 | 2018 |
| Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study NM Chanzá, W Xie, MA Bilen, H Dzimitrowicz, J Burkart, DM Geynisman, ... The lancet oncology 20 (4), 581-590, 2019 | 156 | 2019 |
| Testicular cancer, version 2.2015 RJ Motzer, E Jonasch, N Agarwal, C Beard, S Bhayani, GB Bolger, ... Journal of the National Comprehensive Cancer Network 13 (6), 772-799, 2015 | 124 | 2015 |
| Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study. ST Tagawa, BM Faltas, ET Lam, PJ Saylor, A Bardia, J Hajdenberg, ... Journal of Clinical Oncology 37 (7_suppl), 354-354, 2019 | 86 | 2019 |
| Phase I study of oral rigosertib (ON 01910. Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies DW Bowles, JR Diamond, ET Lam, CD Weekes, DP Astling, RT Anderson, ... Clinical Cancer Research 20 (6), 1656-1665, 2014 | 72 | 2014 |
| Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non–small cell lung cancer patients with K RAS‐activated tumors MA Villalona‐Calero, E Lam, GA Otterson, W Zhao, M Timmons, ... Cancer 122 (6), 875-883, 2016 | 70 | 2016 |
| Safety and efficacy of nivolumab in patients with advanced non–clear cell renal cell carcinoma: results from the phase IIIb/IV CheckMate 374 study NJ Vogelzang, MR Olsen, JJ McFarlane, E Arrowsmith, TM Bauer, ... Clinical genitourinary cancer 18 (6), 461-468. e3, 2020 | 67 | 2020 |
| Kidney cancer, version 2.2014 RJ Motzer, E Jonasch, N Agarwal, C Beard, S Bhayani, GB Bolger, ... Journal of the National Comprehensive Cancer Network 12 (2), 175-182, 2014 | 66 | 2014 |
| Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant? A Amini, B Altoos, MT Bourlon, E Bedrick, S Bhatia, ER Kessler, TW Flaig, ... Practical radiation oncology 5 (6), e589-e596, 2015 | 65 | 2015 |
| SWOG S0925: a randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive … EY Yu, H Li, CS Higano, N Agarwal, SK Pal, A Alva, EI Heath, ET Lam, ... Journal of Clinical Oncology 33 (14), 1601-1608, 2015 | 58 | 2015 |
| Clinical activity and safety of cabozantinib for brain metastases in patients with renal cell carcinoma L Hirsch, NM Chanza, S Farah, W Xie, R Flippot, DA Braun, N Rathi, ... JAMA oncology 7 (12), 1815-1823, 2021 | 53 | 2021 |
| Local control rates of metastatic renal cell carcinoma (RCC) to thoracic, abdominal, and soft tissue lesions using stereotactic body radiotherapy (SBRT) B Altoos, A Amini, M Yacoub, MT Bourlon, EE Kessler, TW Flaig, ... Radiation Oncology 10, 1-8, 2015 | 52 | 2015 |
